2015 Next Generation Dx Summit

Cambridge Healthtech Institute’s Sixth Annual
Companion Diagnostics
Strategy, Partnership, Technology and Adoption
August 18-19, 2015 | Capital Hilton | Washington, DC


The co-development of drugs and diagnostics, i.e. companion diagnostics development, is promising, and in some cases already delivering significant patient benefits, healthcare cost savings, and revenue opportunities. It requires a new business model to fit the emerging strategies in the marketplace. It also carries out most technological advances both as IVD products, and as laboratory developed tests with gene panels and even whole exome sequencing playing a role of companion tests. Cambridge Healthtech Institute’s Sixth Annual Companion Diagnostics: Strategy & Partnerships conference is designed to facilitate knowledge and opinion exchange between pharmaceutical and diagnostics executives, translational scientists, clinicians, business experts, regulators, international companion diagnostics leaders, and other parties involved in drug-diagnostics co-development and precision medicine. Case studies of successful collaboration between pharmaceutical and diagnostics companies’ researchers and executives will be presented.

Preliminary Agenda


MOVING TOWARDS UNIVERSAL COMPANION DIAGNOSTICS 

Development and Application of a Next Generation Sequencing-Based Companion Diagnostic for Prospective Identification of Ovarian Cancer Patients Likely to Respond to Rucaparib

Mitch Raponi, Ph.D., Senior Director, Molecular Diagnostics, Clovis Oncology

Development and Implementation of NGS-Based Companion Diagnostics

Matthew J. Hawryluk, Ph.D., Senior Director, Corporate & Business Development, Foundation Medicine, Inc.


PARTNERSHIP AS THE KEY FEATURE OF DRUG-DIANGOSTICS CO-DEVELOPMENT 

From Pharmacogenomics to FDA-Approved Companion Assays: Road Map and Lessons Learned

Rebecca Blanchard, Ph.D., Executive Director, Genetics and Pharmacogenomics, Head of Clinical Pharmacogenomics, Merck & Co., Inc. 

Internal and External Partnerships in Drug-Diagnostics Co-Development

Carolina Rizo, Ph.D., MBA, Director, Business Development, Roche Molecular Systems

Rx-Dx Collaborations and Co-Development: Delivering on Precision Medicine

George A. Green IV, Ph.D., Group Director, Pharmacodiagnostic Center of Excellence, Bristol-Myers Squibb

Andrea H. Lauber, Ph.D., Executive Director, Business Development, Clinical Biomarkers and Pharmacodiagnostics, Bristol-Myers Squibb

Regulatory Perspective on Multiplex Companion Diagnostic

Eunice Lee, Ph.D., Division of Immunology and Hematology Devices, Office of In Vitro Diagnostics and Radiological Health, CDRH, FDA


CO-COMMERCIALIZATION OF THERAPEUTICS AND DIAGNOSTICS 

Panel Discussion: Why Diagnostics Are Behind Drugs and How We Can Change That

Moderator: Pia Gargiulo, Ph.D., Independent Consultant



For more details on the conference, please contact:
Marina Filshtinsky, M.D.
Senior Director, Conferences
Cambridge Healthtech Institute
T: (+1) 781-972 5496
E: mfilshtinsky@healthtech.com 

For exhibit & sponsorship opportunities, please contact:
Joe Vacca
Associate Director, Business Development
Cambridge Healthtech Institute
T: (+1) 781-972-5431
E: jvacca@healthtech.com 

Japan-Flag Korea-Flag China-Simplified-Flag China-Traditional-Flag 

2014 Brochure

2014 Brochure 


Premier Sponsor

ThermoFisher Scientific logo 


Related Products

MDX_Logo_150x150